Berkshire Hathaway Inc. (BRK-B) vs Eli Lilly and Company (LLY)

See how Berkshire Hathaway Inc. and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.

$505.59
NYSE
View Full Page
$1,162.72
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full Page

Key Metrics Comparison

Berkshire Hathaway Inc.BRK-B
Market Cap
$1.082T
Price
$505.59
24h Change
+0.26%
24h Volume
$1.34M
Employees
387,800
Shares Outstanding
N/A
Eli Lilly and CompanyLLY
Market Cap
$1.036T
Price
$1,162.72
24h Change
+1.71%
24h Volume
$1.1M
Employees
50,000
Shares Outstanding
944,818,881

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

Market Share
BRK-B
51.1%
LLY
48.9%

Volume Share

Share of combined 24h volume

Volume Share
BRK-B
54.9%
LLY
45.1%

24h Performance

Price change over last 24 hours

24h Performance
BRK-B
0.26%
LLY
1.71%
Price Comparison
Berkshire Hathaway Inc.
Eli Lilly and Company